Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma : DESCRIBE-AD real-world retrospective observational study

José L. Manzano, J. Martin-Liberal, Luis A. Fernández-Morales, G. Benítez, J. Medina Martínez, M. Quindós, A. García-Castaño, O. Fernández, R.V. Simo, Margarita Majem, L. Bellido, P. Ayala De Miguel, B. Campos, E. Espinosa, J.A. Macías Cerrolaza, I. Gil-Arnaiz, D. Lorente, A. Rodriguez-Lescure, V.N. Perez, R. López CastroM.G. Gramaje, T. Puértolas, J.F. Rodriguez Moreno, L. Espasa Font, G. Belaustegui Ferrández, P. Cerezuela-Fuentes

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

6 Cites (Scopus)

Resum

BRAF and MEK inhibitor, dabrafenib plus trametinib, adjuvant therapy is effective for high-risk resected melanoma patients with BRAF- mutations. However, real-world evidence is limited. We aimed to determine the feasibility of this therapy in routine clinical practice. DESCRIBE-AD, a retrospective observational study, collected real-world data from 25 hospitals in Spain. Histologically confirmed and resected BRAF-mutated melanoma patients aged ≥18 years who were previously treated with dabrafenib plus trametinib adjuvant therapy, were included. The primary objectives were treatment discontinuation rate and time to discontinuation. The secondary objectives included safety and efficacy. From October 2020 to March 2021, 65 patients were included. Dabrafenib and trametinib discontinuation rate due to treatment-related adverse events (TRAEs) of any grade was 9%. Other reasons for discontinuation included patients' decisions (6%), physician decisions (6%), unrelated adverse events (3%), disease progression (5%), and others (5%). The median time to treatment discontinuation was 9 months [95% confidence interval (CI), 5-11]. G3-4 TRAEs occurred in 21.5% of patients, the most common being pyrexia (3%), asthenia (3%), and diarrhoea (3%). Unscheduled hospitalisations and clinical tests occurred in 6 and 22% of patients, respectively. After 20-month median follow-up (95% CI, 18-22), 9% of patients had exitus due to disease progression, with a 12-month relapse-free survival and overall survival rates of 95.3% and 100%, respectively. Dabrafenib and trametinib adjuvant therapy proved effective for melanoma patients in a real-world setting, with a manageable toxicity profile. Toxicity frequencies were low leading to low incidence of unscheduled medical visits, tests, and treatment discontinuations.
Idioma originalAnglès
Pàgines (de-a)0388-397
Nombre de pàgines10
RevistaMelanoma Research
Volum33
Número5
DOIs
Estat de la publicacióPublicada - 2023

Fingerprint

Navegar pels temes de recerca de 'Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma : DESCRIBE-AD real-world retrospective observational study'. Junts formen un fingerprint únic.

Com citar-ho